Nicolas Robert

St Eloi Hospital
Montpellier, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling.

CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling.

Journal: Translational oncology

Published: May 25, 2026

CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.

CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.

Journal: Oncoimmunology

Published: July 20, 2025

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma.

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma.

Journal: British journal of pharmacology

Published: October 14, 2024

FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population.

FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population.

Journal: Oncoimmunology

Published: August 23, 2024

A case of refractory IgG4-related disease successfully treated with daratumumab and lenalidomide.

A case of refractory IgG4-related disease successfully treated with daratumumab and lenalidomide.

Journal: Rheumatology (Oxford, England)

Published: August 08, 2024

Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction.

Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction.

Journal: Theranostics

Published: August 02, 2024

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma.

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma.

Journal: Blood neoplasia

Published: June 24, 2024

Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma.

Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma.

Journal: Frontiers in oncology

Published: August 03, 2023

Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.

Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.

Journal: European journal of haematology

Published: June 06, 2023

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.

Journal: Leukemia

Published: March 07, 2023

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance.

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance.

Journal: Frontiers in immunology

Published: June 30, 2022

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach.

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach.

Journal: Frontiers in cell and developmental biology

Published: February 18, 2022

Showing 1-12 of 27

Last Updated: 09/26/2026